Get the Stockscreener App
1,064.29
2.12%
-23.09
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,064.29, with a volume of 2.57M.
It is down -2.12% in the last 24 hours and down -0.69% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,087.38
Open:
$1083.73
24h Volume:
2.57M
Relative Volume:
0.74
Market Cap:
$952.56B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
52.64
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+2.49%
1M Performance:
-0.69%
6M Performance:
+33.22%
1Y Performance:
+38.83%
1-Day Range:
$1,063.02
$1,084.32
1-Week Range:
$1,015.96
$1,095.48
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Whittier Trust Co. of Nevada Inc. Buys 2,524 Shares of Eli Lilly and Company $LLY - MarketBeat
Whittier Trust Co. Purchases 6,224 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Kanawha Capital Management LLC - MarketBeat
First Citizens Bank & Trust Co. Purchases 9,121 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Shares Face Pressure as Key Drug Approval Timeline Shifts - AD HOC NEWS
3 Growth Stocks to Invest $1,000 in Right Now - The Motley Fool
Should You Dump Eli Lilly's Shares After This Setback? - The Motley Fool
The Truth About Eli Lilly (NYSEreplacing with LPLA): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week - TechStock²
Guggenheim Reduces PT on Eli Lilly and Company (LLY) to $1,161, Reiterates 'Buy' Rating - Finviz
Eli Lilly and Company $LLY Shares Sold by Symphony Financial Ltd. Co. - MarketBeat
Mn Services Vermogensbeheer B.V. Has $233.24 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Dash Acquisitions Inc. Raises Stake in Eli Lilly and Company $LLY - MarketBeat
Jennison Associates LLC Has $3.20 Billion Holdings in Eli Lilly and Company $LLY - MarketBeat
BAM Wealth Management LLC Invests $1.09 Million in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Shares: Market Experts Maintain Bullish Outlook Despite Recent Weakness - AD HOC NEWS
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? - Finviz
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings - The Globe and Mail
How the CEOs of AI leader Nvidia and drug giant Lilly drove a groundbreaking collaboration - The Business Journals
Bernstein Sees Eli Lilly Stock (LLY) Hitting $1,300 Per Share - TipRanks
Lockheed Martin Investment Management Co. Sells 27,400 Shares of Eli Lilly and Company $LLY - MarketBeat
Vantage Investment Partners LLC Has $39.54 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Spear Holdings RSC Ltd Reduces Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
ELI LILLY & CO (NYSE:LLY) Offers a Durable Dividend with Strong Growth and Financial Health - Chartmill
What obesity drugmakers see next in the market: More pills, easier access and drug combinations - CNBC
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 - Finviz
Cipla Explores Semaglutide Generics Market Entry, Partners with Eli Lilly for Mounjaro Launch - scanx.trade
Eli Lilly and Company $LLY Shares Purchased by Envestnet Portfolio Solutions Inc. - MarketBeat
iA Global Asset Management Inc. Raises Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Strategic Pipeline Developments Amid Market Volatility - AD HOC NEWS
Llamas Are Big Pharma’s Secret Weapon to Find New Drugs - Bloomberg
Eli Lilly’s Strategic Expansion: Pipeline Progress and Financial Outlook - AD HOC NEWS
Nvidia CEO to Lilly CEO: You Were Running Around the Forest … - Dealbreaker
Eli Lilly (LLY) Shines Amid Healthcare Sector's Underperformance - GuruFocus
Eli Lilly and Co's Options Frenzy: What You Need to Know - Benzinga
Vest Financial LLC Buys 2,178 Shares of Eli Lilly and Company $LLY - MarketBeat
Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference - BioSpace
Bey Douglas LLC Reduces Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s Oncology Ambitions Gain Momentum with Key FDA Designation - AD HOC NEWS
Nvidia CEO to Lilly CEO: You were running around the forest … - MedCity News
Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.6%Time to Buy? - MarketBeat
Vital Signs: Unwrapping J&J's $100 billion ambition - FirstWord Pharma
Why Eli Lilly (LLY) Stock Is Up Today - Finviz
Beyond the Silicon: NVIDIA and Eli Lilly Launch $1 Billion ‘Physical AI’ Lab to Rewrite the Rules of Medicine - FinancialContent
Eli Lilly’s Oncology Pipeline Gains Momentum with Key Regulatory Designation - AD HOC NEWS
Stock Yards Bank & Trust Co. Acquires 1,197 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly: Buy Ahead Of Its Earnings Day (Preview) (NYSE:LLY) - Seeking Alpha
First-movers respond to biopharma herding into hot targets - Endpoints News
Rakuten Investment Management Inc. Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Has $137.37 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Joel Isaacson & Co. LLC Acquires 3,976 Shares of Eli Lilly and Company $LLY - MarketBeat
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):